Evidence map›Paper›PMID 33072905›Full record

ArticleHeliyon2020

Anti-tumor effects of

Shilpa R Raju, Sreenath Balakrishnan, Somanna Kollimada, K N Chandrashekara, Aruna Jampani

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. International journal of molecular sciences · 2020
    Article
  5. Anticancer effect ofPakistan journal of medical sciences
    Article
  6. Pakistan journal of medical sciences
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Shilpa R RajuDepartment of Biotechnology, REVA University, Bengaluru, India.
Sreenath BalakrishnanBioSystems Science and Engineering, Indian Institute of Science, Bengaluru, India.
Somanna KollimadaDepartment of Mechanical Engineering, Indian Institute of Science, Bengaluru, India.
K N ChandrashekaraDivision of Plant Physiology and Biotechnology, UPASI Tea Research Foundation, Coimbatore, India.
Aruna JampaniDepartment of Biotechnology, REVA University, Bengaluru, India.
Indian Institute of Science Bangalore · INREVA University · INUPASI Tea Research Foundation · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMATERIAL AND

methodsWe have characterized the biochemical and biomechanical properties of MDA-MB-231 cells treated with the methanolic extract from AN.

resultsWe show that AN-treatment decreases cell-eccentricity, increases expression of actin and microtubules, and do not affect cell-area. Increased expression of cytoskeletal proteins is known to change the mechanical properties of the cells, which was confirmed using micropipette aspiration and Atomic Force Microscopy. We identified the upregulation of the tumorigenic pathway (TGF-β) leading to activation of Rho-A as the molecular mechanism responsible for actin upregulation. Since the initial stages of TGF-β upregulation are known to suppress tumor growth by activating apoptosis, we hypothesized that the mechanism of cell death due to AN-treatment is through TGF-β activation. We have validated this hypothesis by partially recuing cell death through inhibition of TGF-β using Alk-5.

conclusionIn summary, our study reveals the mechanism of action of

Indexed as

Agricultural scienceAnti-tumor effectsArtemisia nilagiricaBiological sciencesCell biologyCell stiffnessChemistryEngineeringHealth sciencesMDA-MB-231 breast cancer cellsNatural product chemistryPharmaceutical chemistryPharmaceutical scienceTGF-β

Identifiers

PMID33072905
PMCPMC7548430
OpenAlexW3092263650

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.